SCHEMBL14009284

SCHEMBL14009284

COc1ccc(NC(=O)c2ccc(C(=O)Nc3ccc(C(N)=O)cc3)s2)c(C)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 3/20 0.50
▸ CA2 P00918 3/20 0.50
▸ SMN1; SMN2 Q16637 3/20 0.50
▸ LMNA P02545 3/20 0.50
▸ CA12 O43570 2/20 0.50
▸ CA9 Q16790 2/20 0.50
▸ KDM4E B2RXH2 2/20 0.50
▸ PLAU P00749 4/20 0.48
▸ F10 P00742 2/20 0.48
▸ PLAT P00750 2/20 0.48
▸ F2 P00734 1/20 0.48
▸ NPC1 O15118 4/20 0.47
▸ RAB9A P51151 4/20 0.47
▸ TP53 P04637 1/20 0.47
▸ ALOX15 P16050 1/20 0.47
▸ MEN1 O00255 2/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ PLG P00747 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.45
▸ MAPT P10636 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14009158 0.90 NPC1 (0.54) CA1CA2SMN1; SMN2LMNACA12
SCHEMBL14009173 0.85 KLKB1 (0.57) CA1CA2SMN1; SMN2LMNACA12
SCHEMBL14009231 0.84 MAPT (0.52) CA1CA2SMN1; SMN2LMNACA12
SCHEMBL14009222 0.83 RXFP1 (0.51) CA1CA2SMN1; SMN2LMNACA12
SCHEMBL14009320 0.82 MEN1 (0.52) CA1CA2SMN1; SMN2LMNACA12
SCHEMBL14009330 0.82 MEN1 (0.52) CA1CA2SMN1; SMN2LMNACA12
SCHEMBL14009166 0.80 HRH3 (0.49) CA1CA2SMN1; SMN2LMNACA12
SCHEMBL14009168 0.80 MAPT (0.57) SMN1; SMN2LMNAKDM4EF10NPC1
SCHEMBL14009239 0.79 RAB9A (0.56) CA1CA2SMN1; SMN2LMNACA12
SCHEMBL14009227 0.79 NPC1 (0.60) SMN1; SMN2F10NPC1RAB9ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7446195-B2 High affinity thiophene-based and furan-based kinase ligands SCHERING CORPORATION (US) 2008-11-04 — — US disclosed
US-7446195-B2 High affinity thiophene-based and furan-based kinase ligands SCHERING CORPORATION (US) 2008-11-04 — — US disclosed
US-20070043045-A1 Novel high affinity thiophene-based and furan-based kinase ligands SCHERING CORPORATION 2007-02-22 — — US disclosed
US-20070043045-A1 Novel high affinity thiophene-based and furan-based kinase ligands SCHERING CORPORATION 2007-02-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043045-A1 Novel high affinity thiophene-based and furan-based kinase ligands CDKL2, CDK2, CDKL1 CA1 4042/4885CA2 2941/4885SMN1; SMN2 2211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback